About US
Contact us
-
Gilead forks over $40M to settle thousands of claims in web of litigation over alleged delay of safer HIV medsAs Gilead Sciences awaits the progression of California state litigation over itsalleged delay of safer HIV drugs, the company is bidingits time with a proposed $40 million settlement to quell the cl2024/5/14
-
Ipsen, Genfit gain FDA approval for Iqirvo in liver disorder, teeing up Intercept showdownOnce hyped as a potential blockbuster medicine for metabolic-associated steatohepatitis (MASH), Ipsen and Genfit’s elafibranor has found its calling as a treatment for a lower-profile liver disorder.2024/5/9
-
After M&A stretch, Pfizer CEO says company needs 'breathing period' from large dealsAmid a recent biopharma M&A resurgence, one major player plans to stay out of the waters after making multiple recent splashes. Though not for lack of business development capacity, Pfizer is cur2024/5/9
-
Colorado drug review board finds J&J's Stelara unaffordable, teeing up potential statewide price capColorado’s Prescription Drug Affordability Review Board (PDAB) isn’t waiting for the Inflation Reduction Act (IRA) to lowerprices oncertain drugs starting in 2026. After the board previously voted to2024/5/7
-
GSK notches Zantac win in Illinois, appeals high-stakes setback in DelawareAs the year rolls on, GSK continues to knock out personal injury lawsuits in the long-running legal saga over whether the popular heartburn medication Zantac can cause cancer. Plaintiff Eugenia Kasza2024/5/7
-
US Supreme Court rejects Vanda's bid to revive patents on sleep disorder drug HetliozThe prospects for Vanda Pharmaceuticals’ 10-year-old circadian rhythm drug Hetlioz have grown that much dimmer after the U.S. Supreme Court shot down the company’s attempt to challenge an appeals cou2024/4/25
-
With $380M deal, Bristol Myers Squibb ups the ante with cell therapy manufacturer CellaresBristol Myers Squibb was the first major biopharma company to take notice of innovative cell therapy contract manufacturer Cellares, participating in a $255 million series C funding round in August o2024/4/25
-
CSL Vifor proposes campaign to undo messaging about safety profile of rival productCSL Vifor hasproposedto launch a campaign that would undo the potentially misleading messages it sent about the safety of a rival product, the European Commission (EC) said. The initiative comes near2024/4/23
-
Roche snags postsurgery FDA nod for Alecensa, eyes even broader lung cancer useRoche isn’t content with Alecensa being the best-selling ALK inhibitor in metastatic lung cancer. The Swiss pharma has now secured FDA approval in the post-surgical setting as it continues to test th2024/4/23
-
Shinobi strikes deal with electronics powerhouse Panasonic to create new cell therapy manufacturing platformHistory is coming full circle as induced pluripotent stem (iPS) cell-derived cell therapy maker Shinobi Therapeutics links up with Panasonic and Japan’s Kyoto University, where the first mouse iPS ce2024/4/18